{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:22:43Z","timestamp":1785435763754,"version":"3.56.0"},"reference-count":47,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of the Czech Republic","award":["NW25-01-00076"],"award-info":[{"award-number":["NW25-01-00076"]}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"crossref","award":["IN 00023001"],"award-info":[{"award-number":["IN 00023001"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007059","name":"Palacky University Olomouc","doi-asserted-by":"publisher","award":["AGA_LF_2026_006"],"award-info":[{"award-number":["AGA_LF_2026_006"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Palacky University Olomouc","doi-asserted-by":"publisher","award":["CZ-OPENSCREEN-LM-2023052"],"award-info":[{"award-number":["CZ-OPENSCREEN-LM-2023052"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Palacky University Olomouc","doi-asserted-by":"publisher","award":["EATRIS-CZ-LM2023053"],"award-info":[{"award-number":["EATRIS-CZ-LM2023053"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"award":["AGA_LF_2026_006"],"award-info":[{"award-number":["AGA_LF_2026_006"]}],"id":[{"id":"https:\/\/ror.org\/04qxnmv42","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CZ-OPENSCREEN-LM-2023052"],"award-info":[{"award-number":["CZ-OPENSCREEN-LM-2023052"]}],"id":[{"id":"https:\/\/ror.org\/04qxnmv42","id-type":"ROR","asserted-by":"publisher"}]},{"award":["EATRIS-CZ-LM2023053"],"award-info":[{"award-number":["EATRIS-CZ-LM2023053"]}],"id":[{"id":"https:\/\/ror.org\/04qxnmv42","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to have beneficial effects in T2D, reducing hepatic lipid storage and improving metabolic dysfunction-associated steatotic liver disease. However, sex and reproductive age may influence their effect. We investigated the effect of liraglutide administration (0.2 mg\/kg\/day subcutaneously for 8 weeks) on metabolic disorders in relation to sex and reproductive age, using male, female and ovariectomized female hereditary hypertriglyceridemic (HHTg) rats as a prediabetic model. Liraglutide improved glucose tolerance in all HHTg rats. Female and ovariectomized (OVX) female rats showed a stronger effect of lipid metabolism and visceral adiposity than males. Moreover, no changes in hepatic triacylglycerol (TAG) accumulation were observed in males. Liraglutide partially reversed ovariectomy effects, such as increased body weight, visceral obesity and impaired glucose tolerance. Compared with males, female and OVX female rats showed more significant changes in hepatic gene expression involved in lipogenesis (Scd-1, Srebp1, Ppar\u03b3), fatty acid and lipid metabolism (Ppar\u03b1, Hmgcr, Srebp2) and fibrosis (Tgf\u03b2), which may improve hepatic lipid metabolism. Females of fertile age showed greater improvements in insulin sensitivity, reductions in ectopic lipid accumulation, and improvements in lipid metabolism. Depending on sex and reproductive status, liraglutide can mitigate fatty liver before diabetes onset.<\/jats:p>","DOI":"10.3390\/antiox15060729","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:50:58Z","timestamp":1781157058000},"page":"729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-Specific and Reproductive Status-Dependent Effects of Liraglutide on Metabolic Disorders Associated with Prediabetes"],"prefix":"10.3390","volume":"15","author":[{"given":"Lucie","family":"Lebertov\u00e1","sequence":"first","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic"},{"name":"First Faculty of Medicine, Charles University, 128 01 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-7636","authenticated-orcid":false,"given":"Irena","family":"Markov\u00e1","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"H\u00fcttl","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"\u010cern\u00e1","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-8848","authenticated-orcid":false,"given":"Iveta","family":"Zapletalov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-3399","authenticated-orcid":false,"given":"Hana","family":"Mal\u00ednsk\u00e1","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients with Type 2 Diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S447182","article-title":"Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK\/mTOR Signaling Pathway","volume":"17","author":"Liao","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/1871530322666220126151141","article-title":"Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease","volume":"22","author":"Zhao","year":"2022","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/dom.70301","article-title":"Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis","volume":"28","author":"Kong","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e70063","DOI":"10.1111\/1753-0407.70063","article-title":"Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis","volume":"17","author":"Yang","year":"2025","journal-title":"J. Diabetes"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"bqae165","DOI":"10.1210\/endocr\/bqae165","article-title":"GLP-1 and Its Analogs: Does Sex Matter?","volume":"166","author":"Borchers","year":"2025","journal-title":"Endocrinology"},{"key":"ref_9","first-page":"70","article-title":"Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause","volume":"23","author":"Nicolau","year":"2025","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111158","DOI":"10.1016\/j.mce.2021.111158","article-title":"Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats","volume":"524","author":"Model","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"116623","DOI":"10.1016\/j.bcp.2024.116623","article-title":"Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism","volume":"230","author":"Model","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_12","first-page":"S19","article-title":"Gender Differences in Nonalcoholic Fatty Liver Disease","volume":"12","author":"Nagral","year":"2022","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"H\u00fcttl, M., Markova, I., Zapletalova, I., and Malinska, H. (2026). Sex-specific aspects in the development of tissue metabolic damage in a non-obese prediabetic model. Front. Endocrinol., 17.","DOI":"10.3389\/fendo.2026.1786893"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.33549\/physiolres.930000.55.S1.49","article-title":"Hereditary hypertriglyceridemic rat: A suitable model of cardiovascular disease and metabolic syndrome?","volume":"55","author":"Zicha","year":"2006","journal-title":"Physiol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Markova, I., Huttl, M., Miklankova, D., Sedova, L., Seda, O., and Malinska, H. (2024). The Effect of Ovariectomy and Estradiol Substitution on the Metabolic Parameters and Transcriptomic Profile of Adipose Tissue in a Prediabetic Model. Antioxidants, 13.","DOI":"10.3390\/antiox13060627"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.nut.2015.03.011","article-title":"Conjugated linoleic acid reduces visceral and ectopic lipid accumulation and insulin resistance in chronic severe hypertriacylglycerolemia","volume":"31","author":"Malinska","year":"2015","journal-title":"Nutrition"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0378-4347(95)00142-6","article-title":"Gas chromatographic analysis of fatty acid methyl esters","volume":"671","author":"Eder","year":"1995","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1476-511X-11-82","article-title":"Long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid or fish oil is associated with increased cardiac content of n-3 fatty acids in rat","volume":"11","author":"Strand","year":"2012","journal-title":"Lipids Health Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"172594","DOI":"10.1016\/j.ejphar.2019.172594","article-title":"Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways","volume":"861","author":"Zhou","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kaneto, H., Kimura, T., Shimoda, M., Obata, A., Sanada, J., Fushimi, Y., Nakanishi, S., Mune, T., and Kaku, K. (2021). Favorable Effects of GLP-1 Receptor Agonist against Pancreatic beta-Cell Glucose Toxicity and the Development of Arteriosclerosis: \u201cThe Earlier, the Better\u201d in Therapy with Incretin-Based Medicine. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157917"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.pbiomolbio.2011.07.005","article-title":"Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells","volume":"107","author":"Leech","year":"2011","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity Management in Adults: A Review","volume":"330","author":"Schwartz","year":"2023","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103925","DOI":"10.1016\/j.nsa.2023.103925","article-title":"GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling","volume":"3","author":"Kooij","year":"2024","journal-title":"Neurosci. Appl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/en.2011-0174","article-title":"Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4","volume":"152","author":"Kanoski","year":"2011","journal-title":"Endocrinology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1073\/pnas.0610787104","article-title":"Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome","volume":"104","author":"Musatov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial","volume":"389","author":"Astrup","year":"2017","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000538996","article-title":"Effect of Liraglutide in Different Abdominal Fat Layers Measured by Ultrasound: The Importance of Perirenal Fat Reduction","volume":"17","author":"Cuatrecasas","year":"2024","journal-title":"Obes. Facts"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., and Kotsa, K. (2022). Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. J. Pers. Med., 12.","DOI":"10.3390\/jpm12030454"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40262-016-0410-7","article-title":"Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis","volume":"55","author":"Overgaard","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_30","first-page":"2579","article-title":"The hereditary hypertriglyceridemic nonobese rat: An experimental model of human hypertriglyceridemia","volume":"22","author":"Vrana","year":"1990","journal-title":"Transplant. Proc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8712979","DOI":"10.1155\/2019\/8712979","article-title":"The Effect of Lipotoxicity on Renal Dysfunction in a Nonobese Rat Model of Metabolic Syndrome: A Urinary Proteomic Approach","volume":"2019","author":"Markova","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Niu, S., Chen, S., Chen, X., Ren, Q., Yue, L., Pan, X., Zhao, H., Li, Z., and Chen, X. (2022). Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1046130"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.14373","article-title":"Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes","volume":"23","author":"Dahl","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial","volume":"15","author":"Hermansen","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e32892","DOI":"10.1097\/MD.0000000000032892","article-title":"Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs","volume":"102","author":"Zhao","year":"2023","journal-title":"Medicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.bbalip.2014.07.002","article-title":"Intracellular cholesterol transporters and modulation of hepatic lipid metabolism: Implications for diabetic dyslipidaemia and steatosis","volume":"1842","author":"Soffientini","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-319-70178-3_12","article-title":"Role of Estrogens in the Regulation of Liver Lipid Metabolism","volume":"1043","author":"Palmisano","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Zvibel","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Milani, I., Chinucci, M., Leonetti, F., and Capoccia, D. (2025). MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040855"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s00210-025-04675-x","article-title":"Repurposing of semaglutide by targeting SIRT1 and TGF-beta\/Smad signaling in hepatic fibrosis","volume":"399","author":"Hawary","year":"2026","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"113236","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106786","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaf336","article-title":"Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis","volume":"110","author":"Wang","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.2147\/DDDT.S224688","article-title":"Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways","volume":"13","author":"Luo","year":"2019","journal-title":"Drug Des. Devel Ther."}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/15\/6\/729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:39:25Z","timestamp":1781325565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/15\/6\/729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["antiox15060729"],"URL":"https:\/\/doi.org\/10.3390\/antiox15060729","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}